Annual CFO
-$66.72 M
+$18.36 M+21.59%
December 31, 2023
Summary
- As of February 7, 2025, BDTX annual cash flow from operations is -$66.72 million, with the most recent change of +$18.36 million (+21.59%) on December 31, 2023.
- During the last 3 years, BDTX annual CFO has fallen by -$14.57 million (-27.94%).
- BDTX annual CFO is now -2737.81% below its all-time high of -$2.35 million, reached on December 31, 2017.
Performance
BDTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$11.32 M
+$3.40 M+23.11%
September 30, 2024
Summary
- As of February 7, 2025, BDTX quarterly cash flow from operations is -$11.32 million, with the most recent change of +$3.40 million (+23.11%) on September 30, 2024.
- Over the past year, BDTX quarterly CFO has increased by +$7.04 million (+38.33%).
- BDTX quarterly CFO is now -126.46% below its all-time high of -$5.00 million, reached on June 30, 2019.
Performance
BDTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$61.20 M
+$7.04 M+10.31%
September 30, 2024
Summary
- As of February 7, 2025, BDTX TTM cash flow from operations is -$61.20 million, with the most recent change of +$7.04 million (+10.31%) on September 30, 2024.
- Over the past year, BDTX TTM CFO has increased by +$13.50 million (+18.07%).
- BDTX TTM CFO is now -789.85% below its all-time high of -$6.88 million, reached on March 31, 2019.
Performance
BDTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
BDTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.6% | +38.3% | +18.1% |
| 3 y3 years | -27.9% | +57.2% | +33.4% |
| 5 y5 years | -689.2% | -113.2% | -148.1% |
BDTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +33.4% | at high | +60.4% | at high | +41.3% |
| 5 y | 5-year | -170.4% | +33.4% | -51.3% | +60.4% | -148.1% | +41.3% |
| alltime | all time | -2737.8% | +33.4% | -126.5% | +60.4% | -789.9% | +41.3% |
Black Diamond Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.32 M(-23.1%) | -$61.20 M(-10.3%) |
| Jun 2024 | - | -$14.73 M(-30.5%) | -$68.24 M(+0.5%) |
| Mar 2024 | - | -$21.20 M(+51.9%) | -$67.89 M(+1.8%) |
| Dec 2023 | -$66.72 M(-21.6%) | -$13.96 M(-24.0%) | -$66.72 M(-10.7%) |
| Sep 2023 | - | -$18.36 M(+27.8%) | -$74.70 M(+2.6%) |
| Jun 2023 | - | -$14.37 M(-28.3%) | -$72.81 M(-4.8%) |
| Mar 2023 | - | -$20.03 M(-8.7%) | -$76.51 M(-10.1%) |
| Dec 2022 | -$85.08 M(-15.0%) | -$21.94 M(+33.2%) | -$85.08 M(-2.4%) |
| Sep 2022 | - | -$16.48 M(-8.8%) | -$87.19 M(-10.3%) |
| Jun 2022 | - | -$18.07 M(-36.8%) | -$97.19 M(-6.8%) |
| Mar 2022 | - | -$28.60 M(+18.9%) | -$104.29 M(+4.1%) |
| Dec 2021 | -$100.15 M | -$24.05 M(-9.2%) | -$100.15 M(+9.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$26.48 M(+5.2%) | -$91.88 M(+19.5%) |
| Jun 2021 | - | -$25.16 M(+2.9%) | -$76.88 M(+17.8%) |
| Mar 2021 | - | -$24.45 M(+55.0%) | -$65.28 M(+25.2%) |
| Dec 2020 | -$52.15 M(+111.3%) | -$15.77 M(+37.3%) | -$52.15 M(+18.9%) |
| Sep 2020 | - | -$11.49 M(-15.3%) | -$43.86 M(+16.4%) |
| Jun 2020 | - | -$13.57 M(+19.9%) | -$37.68 M(+29.4%) |
| Mar 2020 | - | -$11.32 M(+51.2%) | -$29.11 M(+18.0%) |
| Dec 2019 | -$24.67 M(+191.9%) | -$7.49 M(+41.0%) | -$24.67 M(+43.6%) |
| Sep 2019 | - | -$5.31 M(+6.2%) | -$17.19 M(+44.7%) |
| Jun 2019 | - | -$5.00 M(-27.3%) | -$11.88 M(+72.7%) |
| Mar 2019 | - | -$6.88 M | -$6.88 M |
| Dec 2018 | -$8.45 M(+259.6%) | - | - |
| Dec 2017 | -$2.35 M | - | - |
FAQ
- What is Black Diamond Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Black Diamond Therapeutics?
- What is Black Diamond Therapeutics annual CFO year-on-year change?
- What is Black Diamond Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Black Diamond Therapeutics?
- What is Black Diamond Therapeutics quarterly CFO year-on-year change?
- What is Black Diamond Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Black Diamond Therapeutics?
- What is Black Diamond Therapeutics TTM CFO year-on-year change?
What is Black Diamond Therapeutics annual cash flow from operations?
The current annual CFO of BDTX is -$66.72 M
What is the all time high annual CFO for Black Diamond Therapeutics?
Black Diamond Therapeutics all-time high annual cash flow from operations is -$2.35 M
What is Black Diamond Therapeutics annual CFO year-on-year change?
Over the past year, BDTX annual cash flow from operations has changed by +$18.36 M (+21.59%)
What is Black Diamond Therapeutics quarterly cash flow from operations?
The current quarterly CFO of BDTX is -$11.32 M
What is the all time high quarterly CFO for Black Diamond Therapeutics?
Black Diamond Therapeutics all-time high quarterly cash flow from operations is -$5.00 M
What is Black Diamond Therapeutics quarterly CFO year-on-year change?
Over the past year, BDTX quarterly cash flow from operations has changed by +$7.04 M (+38.33%)
What is Black Diamond Therapeutics TTM cash flow from operations?
The current TTM CFO of BDTX is -$61.20 M
What is the all time high TTM CFO for Black Diamond Therapeutics?
Black Diamond Therapeutics all-time high TTM cash flow from operations is -$6.88 M
What is Black Diamond Therapeutics TTM CFO year-on-year change?
Over the past year, BDTX TTM cash flow from operations has changed by +$13.50 M (+18.07%)